A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC)

被引：2
|
作者：
Hanna, N
Bonomi, P
Lynch, T
Ansari, R
Govindan, R
Janne, R
Lilenbaum, R
机构：
[1] Indiana Univ, Bloomington, IN 47405 USA
[2] Rush Univ, Chicago, IL 60612 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Michigan Hematol Oncol PC, South Bend, IN USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Mt Sinai Comprehens Canc Ctr, Miami Beach, FL USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80240-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [1] A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC).
    Lynch, TJ
    Lilenbaum, R
    Bonomi, P
    Ansari, R
    Govindan, R
    Janne, PA
    Hanna, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 637S - 637S
  • [2] A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): Final results.
    Lilenbaum, R
    Bonomi, P
    Ansari, R
    Lynch, T
    Govindan, R
    Janne, P
    Hanna, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 629S - 629S
  • [3] Phase II trial of imatinib (I) and docetaxel (D) in recurrent non-small cell lung cancer (NSCLC)
    Huang, C. H.
    Williamson, S.
    Van Veldhuizen, P. J.
    Hsueh, C. T.
    Smith, H.
    Mayo, M.
    Allen, A.
    Kelly, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A phase II trial of adding cetuximab to cisplatin and gemcitabine as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Barata, F.
    Parente, B.
    Teixeira, E.
    Costa, A.
    Fernandes, A.
    Pimentel, F. L.
    Carvalho, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Phase II trial of carboplatin plus cetuximab for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC)
    Bradford, D. S.
    Socinski, M. A.
    LaRocca, R. V.
    Hensing, T. A.
    Bordoni, R. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial
    Anish B. Parikh
    Peter Kozuch
    Nicholas Rohs
    Daniel J. Becker
    Benjamin P. Levy
    [J]. Investigational New Drugs, 2017, 35 : 813 - 819
  • [7] Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial
    Parikh, Anish B.
    Kozuch, Peter
    Rohs, Nicholas
    Becker, Daniel J.
    Levy, Benjamin P.
    [J]. INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 813 - 819
  • [8] A phase II clinical trial of gemcitabine and imatinib mesylate for patients with recurrent non-small cell lung cancer (NSCLC)
    Eleff, M.
    Sovak, M. A.
    Greenberg, D.
    Guensch, L.
    Joyce, P.
    Schwartz, S.
    Zheng, L.
    Aisner, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Rubinsak, J. R.
    Spigel, D. R.
    Hainsworth, J. D.
    Webb, C.
    Inhorn, R. C.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Vazquez, E. R.
    Greco, F. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) Combined with Erlotinib for Patients with Recurrent Non-small Cell Lung Cancer (NSCLC)
    Kavanagh, B.
    Abdulrahman, R.
    Camidge, D. R.
    Gerber, D. E.
    Bunn, P. A.
    Schiller, J.
    Choy, H.
    Gaspar, L.
    Doebele, R.
    Timmerman, R. D.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S15 - S15
12345